Upadacitinib

4 Blockbuster Drug Launches to Watch in 2019
4 Blockbuster Drug Launches to Watch in 2019
Motley Fool
drug launches
AbbVie
Alexion Pharmaceuticals
Aimmune Therapeutics
Skyrizi
psoriasis
Upadacitinib
rheumatoid arthritis
Ultomiris
PNH
AR101
peanut allergy
Flag link:
Forget Humira -- Here's What You Need to Know About AbbVie
Forget Humira -- Here's What You Need to Know About AbbVie
Motley Fool
AbbVie
Humira
Upadacitinib
risankizumab
Rick Gonzalez
Flag link:
AbbVie rheumatoid arthritis drug succeeds in late stage trial
AbbVie rheumatoid arthritis drug succeeds in late stage trial
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
Flag link:
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis
Yahoo/Motley Fool
AbbVie
Gilead Sciences
FDA
rheumatoid arthritis
Upadacitinib
filgotinib
Flag link:
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
3 Reasons to Expect Smooth Sailing for AbbVie's Mission-Critical Candidate
Yahoo/Motley Fool
AbbVie
Huimra
Upadacitinib
rheumatoid arthritis
Flag link:
AbbVie to submit upadacitinib to FDA after 5th trial win
AbbVie to submit upadacitinib to FDA after 5th trial win
Fierce Pharma
AbbVie
Upadacitinib
rheumatoid arthritis
FDA
JAK inhibitors
Flag link:
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
Flag link:
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
AbbVie's Upadacitinib Meets Primary and Key Efficacy Endpoints in Phase 2b/3 Rheumatoid Arthritis Study
CP Wire
AbbVie
rheumatoid arthritis
Upadacitinib
clinical trials
Flag link:
With study success, AbbVie's arthritis hopeful looks to be a safer bet
With study success, AbbVie's arthritis hopeful looks to be a safer bet
Biopharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
Humira
clinical trials
Flag link:
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
AbbVie Presents New Data on Upadacitinib for Crohn's Disease
Yahoo/Zacks.com
AbbVie
Upadacitinib
Crohn's Disease
Flag link:
These 3 Drugs Are Critical to AbbVie's Success
These 3 Drugs Are Critical to AbbVie's Success
Motley Fool
AbbVie
Rova-T
Upadacitinib
risankizumab
Flag link:
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
ABBV to Focus on Advancing Late-Stage Immunology Research in 2018
Market Realist
AbbVie
R&D
immunology
Upadacitinib
risankizumab
Flag link:
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Why AbbVie's Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis
Market Realist
AbbVie
Upadacitinib
rheumatoid arthritis
Flag link:
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
Another death mars AbbVie’s latest batch of promising data for its star rheumatoid arthritis drug
BioPharma Dive
AbbVie
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
AbbVie keen on JAK inhibitor despite safety concerns
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
AbbVie
JAK inhibitors
Upadacitinib
ABT-494
rheumatoid arthritis
Flag link:
AbbVie reports two patient deaths in rheumatoid arthritis study
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
AbbVie
clinical trials
rheumatoid arthritis
Upadacitinib
ABT-494
Flag link:
AbbVie preps JAK atopic dermatitis candidate for phase 3
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
AbbVie
JAK inhibitors
clinical trials
atopic dermatitis
Upadacitinib
Sanofi
Regeneron
Dupixent
Flag link:
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
AbbVie
ABT-494
atopic dermatitis
Upadacitinib
Flag link:
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
AbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know
Motley Fool
AbbVie
Humira
Upadacitinib
JAK inhibitors
autoimmune disease
Flag link:
First PhIII trial of AbbVie’s upadacitinib a success
First PhIII trial of AbbVie’s upadacitinib a success
Pharma Times
AbbVie
Upadacitinib
clinical trials
rheumatoid arthritis
Flag link:

Pages